Content
57
Yahoo Finance
01/25
(Community Post)
Hablahsi,I will gladly discuss any of the data I am using that reinforces why I think the MRD conversion rate delta is going to fall in the high range with you. You always shy away from discussing the data and just want to attack me.I am here any time you want to have a civil discussion on the data or mechanisms.For example:We could talk about why Rituximab in R-CHOP is highly effective in clearing the bulky disease, until it starts to show its limitations to get in the nooks and crannies. This is where a CAR-T cell therapy can come in and mop up quite easily. The mAb and CAR-T together match up quite nicely as a one two punch combo in consolidation. Or we can talk about the CD20 molecules vs the CD19 molecules and how they spread out across the cancer cell, again giving an advantage to Cema-cel …...
31
Watchlist News
01/25
Zachary Roberts Sells 26,269 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) EVP Zachary Roberts sold 26,269 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an…...
57
Yahoo Finance
01/25
(Community Post)
Keise Bum, there is absolutely nothing to discuss in your data; it's all made up. Very similar to your certainty in explaining why Management did not present two weeks ago at the JPM Healthcare conference - how did you present it? - It's because they are in negotiations with a buyer…..everything you post is made up mostly nonsense geared towards individuals easily manipulated. Your posts on why Cemacel will be approved in 2024 and 2025 were also very well articulated, primarily geared towards those who have no clue about this space. You are like the fake sign language interpreter who is making up gestures, asking, 'What's wrong with my signs?' You are just making it all up - for what purpose? Same as the fake interpreter - it's unfortunate for anyone reading your posts by the time they understand it's all made up, Keiser Bum is just a boiler room …...
57
Yahoo Finance
01/25
(Community Post)
hablahsi,There is plenty to discuss in the data I present. Most of the trial data I present comes from the Yescarta, Breyanzi, Caribou, and Allogene trials. None of it is made up, but it is your job to say that and lie. The mechanisms are clearly defined and not made up.Every message I posted during JPM was about Allogene's position of strength. Allogene is right where they want to be right now, and their doors are open for strategic interest. The Biopharma Dealmakers' marketing is an official public display of that at the time of the JPM event. Allogene is highly likely to already be in discussions with strategic interest. This is how biotech works, they do not just start talking after these major milestones that are approaching.I never stated Cema-cel would be approved in 2024. I stated for mid 2025 if they were to present with strong first leg …...
57
Yahoo Finance
01/25
(Community Post)
VERIFY: Here are peer reviewed references that you MUST read:“CAR-T cell expansion: harmful or helpful?” (Blood Advances, 2024)CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas / published in nature...
57
Yahoo Finance
01/25
(Community Post)
The more plausible interpretation is uncomfortable but straightforward: management is already seeing concerning safety and immune suppression signals. They understand the mechanism driving those signals—excessive expansion and T-cell disruption—and they are choosing to disclose it now to establish a record. When the program is ultimately discontinued, they will be able to say that investors were informed of the underlying biology and the associated risks. They wanted to avoid any potential lawsuits for hiding CRITICAL Information that can drive severe safety issues.The delayed POC timeline reinforces this view. The company is not waiting because responses are rapidly emerging; they are waiting to see whether any durable remission can justify the substantial safety burden they are observing. They are also waiting to understand whether immune function recovers—or whether patients are left chronically vulnerable.The critical unanswered question is not whether ALLO-329 expands. It is whether the immune system recovers intact after that expansion.Right …...
57
Yahoo Finance
01/25
(Community Post)
There are several points here that deserve serious, critical scrutiny.If ALLO-329 were truly performing well and particularly if it were “winning” in the non-chemo arm , then the company’s recent choice of messaging makes little scientific or strategic sense. Why highlight a 10–20× expansion advantage versus lymphodepletion, drawn entirely from preclinical mouse data, in a corporate presentation now? If the plan to share the true HUMAN data in June, why to share preclinical data now? what do they want to achieve or tell?That is not a clinically rigorous endpoint, and it is not a value-driving disclosure. Expansion alone does not predict efficacy, durability, or safety in autoimmune disease. It does not move share price meaningfully, it does not de-risk the program, and it certainly does not justify investor enthusiasm. So what is the purpose of sharing it?If management believed this signal were genuinely bullish, the rational strategy would be to …...
57
Yahoo Finance
01/25
(Community Post)
Let me try this again but in a lot fewer words. Maybe I'll get a response and maybe not a thumbs down.If allo 329 gets dropped and Alpha 3 cemal cel only potential pipeline on the line. Where does anyone see potential high price on FDA approval or buy out?...
57
Yahoo Finance
01/25
(Community Post)
Verify. if you just check this reference “CAR-T cell expansion: harmful or helpful?” (Blood Advances, 2024) and see table 1, and the references cited in this table, all of them point to the same conclusion. Allo 329 will be DROPPED by the end of H1 2026....
57
Yahoo Finance
01/25
(Community Post)
Mo, the market is taking all the Allogne news as very positive.The analysts know what is coming with Alpha3 or have a very good idea where they are going to land.The new 10 to 20 times better expansion with the Allo-329 No LD vs Allo-329 with LD from the preclinical data now shows something very important for autoimmune reset. This very unique allogeneic dual CAR-T can expand by not just one order of magnitude but it can expand by two orders of magnitude with NO CHEMO. This is the same order of magnitude that an anti cd19 autologous CAR-T with LD can expand. This same expansion ability was shown in 316 in the oncology setting.No allogeneic CAR-T has ever shown this capability, and to do it without LD is unheard of.Sure Mo will try to attack this phenomena as "Dangerous", but Mo has proven himself as an unreliable source of …...
57
Yahoo Finance
01/25
(Community Post)
Allogene’s absence from JPM was deliberate. ALLO-329 is showing serious safety issues, and appearing at JPM would have forced management into an impossible position: either be honest and trigger an immediate sell-off, or stay vague and expose the company to serious legal risk once the data emerges. Skipping the conference avoided both.The strategy appears to be delay and sequencing. Push scrutiny past JPM, wait for ALPHA-3 to generate something positive, use that to stabilize or reprice the stock, raise capital while sentiment is temporarily improved, and only then discontinue ALLO-329. This looks less like execution risk and more like damage control....
57
Yahoo Finance
01/25
(Community Post)
In autoimmune indications, the FDA’s tolerance for CAR-T toxicity is fundamentally different from oncology. These are not terminal cancer patients. The acceptable bar is effectively near-zero ICANS and almost entirely Grade 1 CRS, with Grade ≥3 events expected to be rare to nonexistent. Anything beyond that is extremely difficult to justify when safer biologics already exist.Now look at ALLO-329’s own biology. The company is highlighting 10–20× higher expansion without lymphodepletion. In oncology, expansion is often celebrated. In autoimmune disease, it is a red flag. The peer-reviewed CAR-T literature is clear: higher expansion and exposure (Cmax, AUC) correlate with higher rates and severity of CRS and ICANS, as well as downstream immune toxicity. Expansion is not free, it comes with inflammatory cost.If ALLO-329 truly expands 10–20× more in the non-chemo arm, then even under conservative assumptions the immune insult scales upward. That means higher cytokine burden, greater neurotoxicity risk, and more …...
57
Yahoo Finance
01/25
(Community Post)
If ALLO-329 truly expands 10–20× more in the non-chemo arm, then even under conservative assumptions the immune insult scales upward. That means higher cytokine burden, greater neurotoxicity risk, and more profound immune disruption. This is precisely the opposite of what the FDA will tolerate in autoimmune disease.Critically, this also invalidates the core thesis of ALLO-329. The entire rationale was that removing chemotherapy would improve safety. Instead, the non-chemo arm appears more dangerous than the chemo arm because expansion itself becomes the dominant driver of toxicity. If the “safer” arm carries higher CRS/ICANS risk than the LD arm, the strategy collapses.There is no regulatory path where the FDA accepts:Meaningful CRS or ICANS riskIn a non-malignant populationDriven by excessive expansionWith uncertain durability and immune recoveryThis is why the messaging has shifted to preclinical expansion instead of clinical outcomes. And this is why ALLO-329 ultimately has only one end state: it will be …...
57
Yahoo Finance
01/25
(Community Post)
"This user is muted" is desperate this weekend, never seen that many posts before. Guess does not appreciate stock direction and working overtime during weekend. Congratz to muted one, you are close to convincing nobody. Whatever was written, I am sure it is not legit. This will only get worse tomorrow....
57
Yahoo Finance
01/25
(Community Post)
Autoimmune disease is a completely different biological problem. There is no bulky tumor, no 10 to the eleventh or 10 to the twelfth cell antigen mass, and no need for lymphoma scale expansion. The goal is temporary suppression of a much smaller, diffuse B-cell factory and reactive T cell compartment to allow immune reset. That’s why modest, controlled expansion without chemo is a feature, not a flaw. This is how Dagger is designed to flow throw the blood.Presenting preclinical expansion data now isn’t a “tell” of failure, it’s explaining why a no lymphodepletion strategy is biologically plausible before human readouts arrive, which the company has consistently guided for 1H 2026.Claiming this oncology toxicity paper somehow proves ALLO-329 will be abandoned is not scientific skepticism, it’s applying the wrong framework to the wrong disease and then drawing a conclusion the authors themselves never make....
57
Yahoo Finance
01/25
(Community Post)
Mediocre pumper. dumpb , a super dumpb mediocrethe Blood Advances piece is written from an oncology CAR-T lens. But the mechanistic takeaways are exactly what make ALLO-329 riskier in autoimmune, not safer:The paper does not say “expansion is bad.” It says expansion is a double-edged variable: higher expansion correlate with higher CRS/ICANS, and expansion does not reliably predict durable benefit in multiple settings. That’s the key point.That point absolutely translates to autoimmune—if anything, it strengthens the bearish view. Autoimmune has a much lower tolerance for CRS/ICANS and systemic immune toxicity than lymphoma. So if “more expansion” can raise toxicity risk without guaranteeing durability in cancer, it’s even more concerning in non-malignant patients where the risk-benefit bar is stricter.No one needs the paper to “predict a drop.” The paper is being used to support a narrower claim: expansion is not a surrogate for durable efficacy and can be tied to toxicity. …...
57
Yahoo Finance
01/25
(Community Post)
There are several points here that deserve serious, critical scrutiny.If ALLO-329 were truly performing well and particularly if it were “winning” in the non-chemo arm , then the company’s recent choice of messaging makes little scientific or strategic sense. Why highlight a 10–20× expansion advantage versus lymphodepletion, drawn entirely from preclinical mouse data, in a corporate presentation now? If the plan to share the true HUMAN data in June, why to share preclinical data now? what do they want to achieve or tell?That is not a clinically rigorous endpoint, and it is not a value-driving disclosure. Expansion alone does not predict efficacy, durability, or safety in autoimmune disease. It does not move share price meaningfully, it does not de-risk the program, and it certainly does not justify investor enthusiasm. So what is the purpose of sharing it?If management believed this signal were genuinely bullish, the rational strategy would be to …...
57
Yahoo Finance
01/25
(Community Post)
This is a fundamental misread of the article being cited. The Blood Advances paper Mo is referencing is about oncology CAR-T in lymphoma, not autoimmune disease, and its main finding is not “expansion is bad” or “programs get dropped.”What the paper actually shows is that in high tumor burden cancers, bigger CAR-T expansion often correlates with higher toxicity (ICANS/CRS). Importantly, the authors explicitly note that in several settings, expansion did NOT reliably predict durable response or PFS. In other words, massive expansion isn’t required for efficacy, and can even be harmful in cancer.None of that translates into “ALLO-329 will be dropped.” That leap is invented. The paper does not say it, imply it, or even address autoimmune CAR-T programs. Once again, Mo shows to us how he does not understand what is going on in these modalities and settings. He has done this time and time again on this board …...
57
Yahoo Finance
01/25
(Community Post)
The more plausible interpretation is uncomfortable but straightforward: management is already seeing concerning safety and immune suppression signals. They understand the mechanism driving those signals—excessive expansion and T-cell disruption—and they are choosing to disclose it now to establish a record. When the program is ultimately discontinued, they will be able to say that investors were informed of the underlying biology and the associated risks. They wanted to protect themselves against any potential lawsuits for hiding CRITICAL Information that can drive severe safety issues.The delayed POC timeline reinforces this view. The company is not waiting because responses are rapidly emerging; they are waiting to see whether any durable remission can justify the substantial safety burden they are observing. They are also waiting to understand whether immune function recovers—or whether patients are left chronically vulnerable.The critical unanswered question is not whether ALLO-329 expands. It is whether the immune system recovers intact after …...
57
Yahoo Finance
01/25
(Community Post)
Mo you can keep throwing spaghetti on the wall, but your lack of understanding is the big problem here. Please keep going, but the market is telling us what they are doing here - they are repositioning.Alpha3 and Resolution could be an unstoppable One Two punch in this patent cliff year of 2026Good day Mo!...
57
Yahoo Finance
01/25
(Community Post)
Ah yes, public wisdom , the mediocre pumper, that sacred shrine of dumb mediocrity.Behold the super dumpbbbb mediocre: Knows absolutely nothing about science, even less about investing. When his nonsense gets dismantled piece by piece and completely destroyed, he doesn’t argue back because he can’t. No facts. No logic. No evidence. Nothing. So what does he do?He cries: “Read more.”Read what, exactly? A tweet? A vibe? The sacred whispers of his own ignorance?Guide me to one reference. Just one.Not a single citation. Not one data point. Not even a badly misunderstood graph he could hide behind.Just pure intellectual bankruptcyLOL. Dumpbbb mediocre. LOL....
57
Yahoo Finance
01/25
(Community Post)
Keiser Bum, Cursing, Mo, Justinas, all the same individual multiple profiles. Keiser Bum seems to believe the numerous profiles route of extreme theories, promotes credibility for Keiser Bum's incompetent thesis, not to mention creates space when their argument breaks down completely. Yesterday again, Keiser Bum falsified that it never promoted 2024 approval for Cemacel - Keiser Bum somehow now wants one to forget they deleted 99% of its posts from 2024 and 2025, all making claims of approvals, stock prices, and buyouts during that period. To add insult Keiser Bum suggests it only promoted mid-year 2025 approval based on “60 patients for the first leg…” again Keiser Bun creates its own reality - the initial 3-arm trial of Alpha-3 called for 12 patients per arm for LD selection and initial MRD% conversion rate; very similar to the current 12 patients per arm - we need now 24 for the Futility …...
57
Yahoo Finance
01/25
(Community Post)
The hanasi user has been getting very sloppy lately.The user will delete this message of incorrect arm information in the late hours. This has happened before but the frequency has increased.Update:The hanasi user has been different during the weekday, weeknight, and weekend coverage. Not sure if other Longs are noticing the difference in the user's posts. This user deletes posts that are totally off script later in the early morning hours EST. The Belligerence has kicked way up; definitely changing tactics as things are tightening up here. The Mo user is still the same belligerent user as before with the same lack of understanding of the science, but the targeting of Allo-329 has been kicked up a notch. This noticeable activity is a good sign....
Votes:
1
0
57
Yahoo Finance
01/26
(Community Post)
Keiser Bum and crew are equity line enthusiasts; they negotiate a defined number of equity shares and, regardless of price, are paid a set fee per share sold, this activity is a last resort and couses share price to decline actively, there are no volume limitations; Keiser Bum’s boiler room tries actively to increase price and markets the shares heavily before selling activity initiates. Keiser Bum is testing the grounds….GOOD LUCK!...
57
Yahoo Finance
01/26
(Community Post)
It’s funny how genuinely strong stocks attract the weakest commentary. Solid fundamentals, real science, and a management team executing the plan yet somehow the loudest voices are the least informed.Too many analysts talking with confidence instead of competence. Lots of opinions, very little understanding. People claiming insight without doing the work.If you trust the science and trust the management, the rest is just background noise. Don’t let neck-talkers and bad actors scare you out of a good investment. Ignore the circus. Stick with the signal....
Votes:
3
1
57
Yahoo Finance
01/26
(Community Post)
The mediocre pumper is trying hard to distract from the hard facts surrounding ALLO-329. The program is on track to be dropped by the end of H1 2026. Management knows this and has already moved to insulate itself from the inevitable fallout and potential lawsuits....
57
Zacks
01/26
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Zacks Equity Research Mon, January 26, 2026 at 9:40 AM EST 2 min read ALLO ALZN Investors interested in Medical stocks shou...
57
Yahoo Finance
01/26
(Community Post)
The more plausible interpretation is uncomfortable but straightforward: management is already seeing concerning safety and immune suppression signals. They understand the mechanism driving those signals—excessive expansion and T-cell disruption—and they are choosing to disclose it now to establish a record. When the program is ultimately discontinued, they will be able to say that investors were informed of the underlying biology and the associated risks. They wanted to protect themselves against any potential lawsuits for hiding CRITICAL Information that can drive severe safety issues.The delayed POC timeline reinforces this view. The company is not waiting because responses are rapidly emerging; they are waiting to see whether any durable remission can justify the substantial safety burden they are observing. They are also waiting to understand whether immune function recovers—or whether patients are left chronically vulnerable.The critical unanswered question is not whether ALLO-329 expands. It is whether the immune system recovers intact after …...
57
Yahoo Finance
01/26
(Community Post)
There are several points here that deserve serious, critical scrutiny.If ALLO-329 were truly performing well and particularly if it were “winning” in the non-chemo arm , then the company’s recent choice of messaging makes little scientific or strategic sense. Why highlight a 10–20× expansion advantage versus lymphodepletion, drawn entirely from preclinical mouse data, in a corporate presentation now? If the plan to share the true HUMAN data in June, why to share preclinical data now? what do they want to achieve or tell?That is not a clinically rigorous endpoint, and it is not a value-driving disclosure. Expansion alone does not predict efficacy, durability, or safety in autoimmune disease. It does not move share price meaningfully, it does not de-risk the program, and it certainly does not justify investor enthusiasm. So what is the purpose of sharing it?If management believed this signal were genuinely bullish, the rational strategy would be to …...
57
Yahoo Finance
01/26
(Community Post)
Now its clear why there was 1000 posts over the weekend by same person. This is 100% short attack and has zero to do with company. Another good day to add. Management did not release any data, some random guy here quoting irrelevant data not even linked to Allogene and claim to know data better than the company itself. Let him post, in the meantime - its opportunity for everyone. I will be here on April watching that smile being washed of of that con man face....
Votes:
2
0
57
Yahoo Finance
01/26
(Community Post)
If ALLO-329 truly expands 10–20× more in the non-chemo arm, then even under conservative assumptions the immune insult scales upward. That means higher cytokine burden, greater neurotoxicity risk, and more profound immune disruption. This is precisely the opposite of what the FDA will tolerate in autoimmune disease.Critically, this also invalidates the core thesis of ALLO-329. The entire rationale was that removing chemotherapy would improve safety. Instead, the non-chemo arm appears more dangerous than the chemo arm because expansion itself becomes the dominant driver of toxicity. If the “safer” arm carries higher CRS/ICANS risk than the LD arm, the strategy collapses.There is no regulatory path where the FDA accepts:Meaningful CRS or ICANS riskIn a non-malignant populationDriven by excessive expansionWith uncertain durability and immune recoveryThis is why the messaging has shifted to preclinical expansion instead of clinical outcomes. And this is why ALLO-329 ultimately has only one end state: it will be …...
57
Yahoo Finance
01/26
(Community Post)
Quality over quantity. We’re seeing a lot of contradictory noise' from Cursing the mediocre pumper lately. Serious investors generally don't spend their day attacking others for no reason. It’s highly likely this is a non-shareholder simply looking to Troll....
57
Yahoo Finance
01/26
(Community Post)
Verify. if you just check this reference “CAR-T cell expansion: harmful or helpful?” (Blood Advances, 2024) and see table 1, and the references cited in this table, all of them point to the same conclusion. Allo 329 will be DROPPED by the end of H1 2026....
57
Yahoo Finance
01/26
(Community Post)
Verify. if you just check this reference “CAR-T cell expansion: harmful or helpful?” (Blood Advances, 2024) and see table 1, and the references cited in this table, all of them point to the same conclusion. Allo 329 will be DROPPED by the end of H1 2026....
57
Yahoo Finance
01/26
(Community Post)
The data they chose to share is not human, not durable, and not outcome-based. It is mechanistic and preliminary. More importantly, it points to a liability, not a strength. A product that expands 10–20× more than with chemotherapy is delivering an extreme biological perturbation. In autoimmune disease, that level of expansion—particularly when driven by host T-cell targeting and suppression—raises immediate red flags around immune competence, infection risk, cytopenias, and long-term immune dysfunction.The safety bar in autoimmune disease is extraordinarily high. These are not terminal oncology patients. Even moderate, chronic immune suppression is unacceptable. A therapy that risks destabilizing the immune system at that magnitude must deliver near-complete, durable remission to justify itself—and even then, the tradeoff is questionable....
57
Yahoo Finance
01/26
(Community Post)
The more plausible interpretation is uncomfortable but straightforward: management is already seeing concerning safety and immune suppression signals. They understand the mechanism driving those signals—excessive expansion and T-cell disruption—and they are choosing to disclose it now to establish a record. When the program is ultimately discontinued, they will be able to say that investors were informed of the underlying biology and the associated risks. They wanted to protect themselves against any potential lawsuits for hiding CRITICAL Information that can drive severe safety issues.The delayed POC timeline reinforces this view. The company is not waiting because responses are rapidly emerging; they are waiting to see whether any durable remission can justify the substantial safety burden they are observing. They are also waiting to understand whether immune function recovers—or whether patients are left chronically vulnerable.The critical unanswered question is not whether ALLO-329 expands. It is whether the immune system recovers intact after …...
57
Yahoo Finance
01/26
(Community Post)
"Cursing something" go home, relax, there is life outside. You been trolling and spreading false information since saturday. Everybody knows where you stand, why you repeat 1000 times, we dont care, seriously. Watch your posts dissapear as I report you for spamming. This guy has no soul, a true criminal....
57
Yahoo Finance
01/26
(Community Post)
VERIFY:Here are peer reviewed references that you MUST read:“CAR-T cell expansion: harmful or helpful?” (Blood Advances, 2024)CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas / published in nature...
57
Yahoo Finance
01/26
(Community Post)
Allo-329 is projected by the company to be able to capture greater than $15 Billion in revenue. There are over 500K patients alone in the United States for the three indications in this basket study. That is worth over $200B. They just want a piece of this market....
57
Yahoo Finance
01/26
(Community Post)
So far Mo has posted bogus information on Allo-329.He has no evidence on safety. What is actually being indicated from the trial site expansion is the trial is executing smoothly going from 2 to 4 to 9 trial sites at this point. This does not happen without the safety monitoring group allowing the site expansion to take place. This does not happen unless the safety gates are passed.Allogene has let us know that they are seeing in more than one human what was seen in the preclinical data. All signs are very positive at this point. Mo is presenting a false narrative to retailers that should be pushed back on....
57
Yahoo Finance
01/26
(Community Post)
Verify. if you just check this reference “CAR-T cell expansion: harmful or helpful?” (Blood Advances, 2024) and see table 1, and the references cited in this table, all of them point to the same conclusion. Allo 329 will be DROPPED by the end of H1 2026....
57
Yahoo Finance
01/26
(Community Post)
So far Mo has posted bogus information on Allo-329.He has no evidence on safety. What is actually being indicated from the trial site expansion is the trial is executing smoothly going from 2 to 4 to 9 trial sites at this point. This does not happen without the safety monitoring group allowing the site expansion to take place. This does not happen unless the safety gates are passed.Allogene has let us know that they are seeing in more than one human what was seen in the preclinical data. All signs are very positive at this point. Mo is presenting a false narrative to retailers that should be pushed back on....
57
Yahoo Finance
01/26
(Community Post)
Mo you did the same thing with FT819. This therapy leaves patients with stall outs. I you compared the results with Breakfree-1 you can see the problem with FT819. FT819 clears out the B cell factory but all the other lupus structures are intact. As soon as the host system is able to fight, it clears out FT819 cells and the lupus starts right back with dsDNA being produced.This is the problem with FT819. The proof is in the patients results....
57
Yahoo Finance
01/26
(Community Post)
Mo you did the same thing with FT819. This therapy leaves patients with stall outs. I you compared the results with Breakfree-1 you can see the problem with FT819. FT819 clears out the B cell factory but all the other lupus structures are intact. As soon as the host system is able to fight, it clears out FT819 cells and the lupus starts right back with dsDNA being produced.This is the problem with FT819. The proof is in the patients results....
Votes:
1
0
57
Yahoo Finance
01/26
(Community Post)
Science is published in papers, books, ..etc. Show me a single evidence for any garbage you are saying. Show me a single reference disproving my predictions. just a single reference for the relation between expansion and toxicity. just one. one only one. just one , man...
57
Yahoo Finance
01/26
(Community Post)
Mo the evidence shows that the sites have expanded from 2 sites to 4 sites to 9 sites. This is all in alignment with a smooth running trial that only expands its foot print when the safety allows it to do so. The safety gates have been passed for this to happen.You say fratricide is taking place but there is no evidence of that. Again the trial sites have expanded in alignment with a smooth running trial. The fact that Allogene has elevated previous undisclosed preclinical data that show 10 to 20 times expansion in the no chemo arm compared to the chemo arm shows that they are seeing this in humans. Dagger is not killing itself from this data.The DL1 dose is 20 million cells, the effective Breakfree-1 dose is 25 million cells. The safety gates have been passed. The expansion information you are referring in your cited papers …...
Votes:
1
0
57
Yahoo Finance
01/26
(Community Post)
Mo, nothing has changed with Allogene's strength at this moment in time. Both Alpha3 and Resolution are operating from a position of strength with all the information we have from the January 8th PR, the January 9th Corporate Presentation, and the two analyst's upgrades.You are pushing misinformation for a reason. It just shows what it always has. You do not understand the science. Allogene is in a very strong position. The Short do what they do, but they are playing with fire here....
Votes:
1
0
57
Yahoo Finance
01/26
(Community Post)
I feel comfortable posting that neither Keiser Bun nor Cursing/Mo has any insight into the industry or ALLO in particular. If you disregard anything you might have read in either of their posts over the last several months and focus only on the actual data presented by ALLO, then we are relatively close to where we need to be. 12.31.2025 we closed at $1.36; other than the company firming up when in the second quarter, we should expect Cemacel Alpha-3 initial data readout of MRD conversion rate and futility analysis, as well as targeting proof of concept of ALLO-329 towards the end of second quarter 2026 - other than that we have not received any additional data and are trading at a higher but wider range. You should not have gotten too excited last week when we increased by 8%; today's decrease could be for any number of reasons unrelated …...
Votes:
1
6
57
Yahoo Finance
01/26
(Community Post)
Is this an old fashioned short attack before news or insider activity or trial tea leaves or SEC filing that hasn't been posted yet? if the broader market was down as well i would understand, but this is definitely targeted to Allogene. Curious if anyone has insight. I'm solidly holding, but have recommended this stock to others and curious on their behalf's. Long and strong ALLO....
Votes:
1
0
57
Yahoo Finance
01/26
(Community Post)
Wow, I thought I wont have a chance to add anymore, but hats down to shorts, they really did Allogene today, big time play, plus brainwashing on board.I do not respect what they do, but thats my chance to increase my share count after half a year of sitting on cost basis of 1.05 dollar.And no, I will not add today, I will wait for better signal. This is far from done, might bounce in the last hour, but dont be fooled. Look on the bright side guys - you get to buy more shares of the company you really believe in. Anything close to or below 1.4 is a great entry. Ignore this noise and keep buying, thats my suggestion....
Votes:
1
0
57
Yahoo Finance
01/26
(Community Post)
Keyser, I still remember you planning to donate some of money when Allogene delivers. Thats a huge respect from me and I want to highlight it again.Its a thing those bashers would never understand as they have no moral compass. Shorting company trying to cure cancer, thats low in all standards and I believe in Karma. Some things you just dont do, unless you are a bad person. Simple as that....
Votes:
1
0
57
Yahoo Finance
01/26
(Community Post)
Seems like nothing is changed - price is at 1 or 2 or 3. Keyser alone by himself still fighting off all the bloodsuckers everyday just to see more of them coming. No wonder, I had to take months break and forget about board for a while. There is a thing called Karma, everyone gets justice sooner or later, both good and bad....
57
Yahoo Finance
01/26
(Community Post)
Is there a normal website with legit discussions about science and observations as pipeline progresses? This board is just a bunch of kids with zero morals posting false information which you can lookup yourself and confirm to be false in 2 minutes. Keyser, if you ever think of sharing your observations somewhere else, let me know. It feels like surfing through garbage - all the good information is buried by some trolls who does not even own a stock and yet posting here nonstop....
Votes:
1
4
57
Yahoo Finance
01/26
(Community Post)
Not great price action today. Just about everything in the sector is down today, but ALLO is down twice as much and on very big volume. It’s slightly reminiscent of just before the patient death was announced. Hopefully this is nothing. But hard not to be a little nervous....
Votes:
4
1
57
Yahoo Finance
01/26
(Community Post)
Allogene did their Greenfield announcement about 4hrs ago on all their social media platforms. No SEC filings as of today yet.This a very quiet time now before any speaking from Allogene. The are focused on execution until the release of the Futility Analysis. This is the perfect time for hedge funds to play. I added before the close and I will keep on adding when they give me these opportunities. These hedge funds and posters like Mo, hanasi, Ricky, Robert, Glenn, etc., know how to work retail. Do not let them take you away from the prize.Allogene knows the games they play as well. Allogene may have something up their sleeves for this time as well. Stay alert but do not give into these Short players....
Votes:
3
0
57
Yahoo Finance
01/26
(Community Post)
Johns Hopkins The addition of Johns Hopkins as a Resolution trial site will rip the rug out from Mo and his lies. A tier 1 academic center does not activate CAR-T trials with unresolved safety issues. I just want to make that clear. Their IRB, IBC, and cell therapy committees are among the most conservative in the country.But even before that, rapid site expansion from 2 to 4 to 9 trial sites in under four months already argues against any hidden safety problem and shows they have cleared safety gates. Trials with real safety concerns do not expand in the sequence we have witnessed for the Resolution trial. They certainly do not expand into elite top tier 1 institutions. Allogene does not elevate the 10 to 20 times better expansion of the No LD arm compared to the LD arm if there were safety issues. This means the expansion potential …...
Votes:
2
0
(Community Post)